Given that HCC is known for its hypervascularity and anti-angiogenic drugs such as bevacizumab are used as first-line treatments for HCC in combination with atezolizumab [22], SORT1 may also act as a promising new therapeutic target for HCC as an anti-angiogenic agent with or without an immune modulator. Here, SORT1 is linked to hepatocellular carcinoma.